Spire Healthcare Group plc (LSE:SPI) has published the scheme document for the final board-backed cash Acquisition by Tulip UK Bidco Limited, a vehicle for a consortium of Toscafund, THCP and Ares. Shareholders will vote at a Court Meeting and a General Meeting on 30 October 2026.
What was announced
Spire Healthcare Group plc (LSE:SPI) published the scheme document on 29 September 2026. It covers the acquisition by Tulip UK Bidco Limited, which acts for funds managed or advised by Toscafund Asset Management LLP, THCP Advisory Limited and Ares Management Limited. The deal is being carried out through a court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006. The scheme document is available at www.investors.spirehealthcare.com and www.toscafund.com.
Shareholders can choose between two forms of consideration: a cash offer and an alternative offer of unlisted rollover securities. The Spire directors unanimously urge Scheme Shareholders to vote in favour of the Scheme in respect of the cash offer. On the alternative offer, the directors say they "are unable to form a view as to whether or not the terms of the Alternative Offer are fair and reasonable".
Meetings and timetable
Both meetings will be held on 30 October 2026 at 3 Dorset Rise, London:
- Court Meeting at 12:00pm, with forms of proxy due by 12:00pm on 28 October
- General Meeting at 12:15pm, with forms of proxy due by 12:15pm on 28 October
- Voting record time of 6:30pm on 28 October 2026
The scheme is expected to become effective in the fourth quarter of 2026 or the first quarter of 2027. The long-stop date is 11:59pm on 4 March 2027. Completion depends on Shareholder approval at both meetings, Court sanction and the other conditions set out in the scheme document, including regulatory conditions. The Rule 2.7 announcement listed FCA approval of the change in control of regulated entities among these. At the Court Meeting, the scheme needs support from shareholders holding at least 75% by value of the scheme shares voted.
The terms agreed in September
The scheme document announcement does not repeat the price. The Rule 2.7 firm offer announcement of 5 September 2026 set the cash offer at 250 pence per share and stated that it is final and cannot be increased. On a fully diluted basis, this valued Spire's Share Capital at about £1,026.5m, and its Enterprise value at about £2,307.6m. The price represented premiums of:
- 66.2% to the closing price of 150.4p on 13 May 2026
- 55.2% to the one-month volume-weighted average price of 161.1p
- 47.2% to the three-month volume-weighted average price of 169.8p
The alternative offer is 2.5 rollover securities per share, capped at 28 million shares, or 8.5% of the scheme shares. The Rule 2.7 announcement describes these securities as unlisted, Illiquid and non-transferable, and subject to drag-along provisions.
Toscafund held about 18.6% of Spire, or 74.9 million shares, at the time of the Rule 2.7 announcement. That announcement reported irrevocable undertakings over about 53.4% of the issued share capital, including 42.2% from Mediclinic Jersey Limited, Harwood Capital Management and Richard Griffiths.
When they backed the cash offer, the directors cited the company's "significant progress", execution risks in the standalone plan and subdued market sentiment. They also described the cash offer as providing "certain value".
Advisers and what to watch next
Rothschild & Co, Perella Weinberg and J.P. Morgan Cazenove advise Spire. Darblay Capital and Panmure Liberum advise the bidder.
The next steps are the proxy deadlines on 28 October and the two shareholder meetings on 30 October. After that come the regulatory clearances, a Court sanction hearing and the scheme becoming effective, all of which must happen before the long-stop date of 4 March 2027. The board has not given a view on the alternative offer.






Please wait processing your request...